Exhibits ATP binding activity; MAP kinase kinase activity; and enzyme binding activity. Involved in several processes, including establishment of vesicle localization; positive regulation of cellular metabolic process; and regulation of intracellular signal transduction. Localizes to several cellular components, including dendrite cytoplasm; glutamatergic synapse; and perikaryon. Colocalizes with microtubule. Used to study cataract and prostate adenocarcinoma. Human ortholog(s) of this gene implicated in bone disease (multiple); carcinoma (multiple); and cardiofaciocutaneous syndrome 3. Orthologous to human MAP2K1 (mitogen-activated protein kinase kinase 1); PARTICIPATES IN the extracellular signal-regulated Raf/Mek/Erk signaling pathway; altered extracellular signal-regulated Raf/Mek/Erk signaling pathway; ceramide signaling pathway; INTERACTS WITH (+)-schisandrin B; 17alpha-ethynylestradiol; 17beta-estradiol 3-benzoate.
Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K1 protein]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Dihydrotestosterone results in increased phosphorylation of and results in increased activity of MAP2K1 protein] more ...
MAP2K1 protein promotes the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein modified form binds to ARNT protein modified form]] more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] more ...
Cyclic GMP affects the reaction [NPPA protein alternative form results in decreased phosphorylation of and results in decreased activity of MAP2K1 protein]
[FSHB protein co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]]
[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K1 protein, Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K1 protein]
[U 0126 results in decreased activity of MAP2K1 protein] results in increased susceptibility to [Fluorouracil co-treated with Cisplatin], MAP2K1 protein results in decreased susceptibility to [Cisplatin co-treated with Fluorouracil]
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of MAP2K1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of MAP2K1 mRNA
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenic trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]] more ...
[Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of MAP2K1 mRNA, [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of MAP2K1 mRNA
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] more ...
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]] more ...
[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K1 protein, Catechin inhibits the reaction [[4-N-methyl-N-nitrosamino-1-3-pyridyl-1-butanone co-treated with Benzoapyrene] results in increased phosphorylation of MAP2K1 protein]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [bicalutamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] more ...
[Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein, [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein
GPER1 mutant form inhibits the reaction [Cadmium results in increased activity of MAP2K1 protein], MAP2K1 protein affects the reaction [Cadmium results in increased expression of PLAUR mRNA]
[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA], Calcium inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]
[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA], Calcium inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
MAP2K1 protein promotes the reaction [Cisplatin results in increased activity of CASP3 protein], MAP2K1 protein promotes the reaction [Cisplatin results in increased phosphorylation of SHC1 protein]
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [cobaltous chloride results in increased activity of [MAPK1 protein co-treated with MAPK3 protein]], [2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] which results in decreased susceptibility to cobaltous chloride
[cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 mRNA, [cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 protein
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein], Mifepristone inhibits the reaction [Dexamethasone inhibits the reaction [EGF protein results in increased phosphorylation of MAP2K1 protein]]
2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one inhibits the reaction [Arsenic Trioxide promotes the reaction [Tretinoin results in increased phosphorylation of and results in increased activity of MAP2K1 protein]] more ...
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Doxorubicin] more ...
[MAP2K1 protein modified form co-treated with AKT1 protein modified form] inhibits the reaction [Gallic Acid inhibits the reaction [EGF protein results in increased expression of MMP9 protein]] more ...
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA
MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased expression of MMP9 protein]], MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of JUN protein]]
MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased expression of MMP9 protein]], MAP2K1 inhibits the reaction [[Gallic Acid binds to Gold] inhibits the reaction [EGF protein results in increased phosphorylation of JUN protein]]
Heparin inhibits the reaction [FGF1 protein results in increased phosphorylation of MAP2K1 protein], Heparin inhibits the reaction [FGF2 protein results in increased phosphorylation of MAP2K1 protein]
bisindolylmaleimide I inhibits the reaction [lead acetate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] more ...
[Lithium results in increased phosphorylation of and results in increased activity of MAP3K8 protein] which results in increased phosphorylation of MAP2K1 protein
[Lithium results in increased phosphorylation of and results in increased activity of MAP3K8 protein] which results in increased phosphorylation of MAP2K1 protein
MAP2K1 protein inhibits the reaction [[2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one co-treated with fludarabine] results in increased cleavage of CASP3 protein]
2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein], 2-4-morpholinyl-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]
myricetin binds to and results in decreased activity of MAP2K1 protein, myricetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MAP2K1 protein]
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] affects the reaction [SOD2 protein results in decreased susceptibility to Paclitaxel] more ...
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Reactive Oxygen Species] more ...
resveratrol inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein], SRT1720 inhibits the reaction [Dinoprost results in increased phosphorylation of MAP2K1 protein]
[2-2-amino-3-methoxyphenyl-4H-1-benzopyran-4-one results in decreased activity of MAP2K1 protein] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased abundance of Reactive Oxygen Species]
[7-hydroxystaurosporine co-treated with Sirolimus] results in decreased expression of MAP2K1 protein, [7-hydroxystaurosporine co-treated with Sirolimus] results in decreased phosphorylation of MAP2K1 protein
Sirolimus inhibits the reaction [MAP2K1 protein results in increased activity of RPS6KB1 protein], Sirolimus inhibits the reaction [MAP2K1 protein results in increased phosphorylation of EIF4EBP1 protein]
[Sumatriptan results in increased abundance of Calcium] inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA], Sumatriptan inhibits the reaction [MAP2K1 protein results in increased expression of CALCA mRNA]
[FSHB protein co-treated with 1-Methyl-3-isobutylxanthine] inhibits the reaction [Testosterone promotes the reaction [RAF1 results in increased phosphorylation of MAP2K1 protein]] more ...
[MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK1 protein], [MAP2K1 protein mutant form results in decreased susceptibility to trametinib] inhibits the reaction [trametinib results in decreased phosphorylation of MAPK3 protein]
[Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein, MAP2K1 protein mutant form results in decreased activity of [perifosine co-treated with vorinostat]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
